Requirement of cholesterol in the viral envelope for dengue virus infection

•Cholesterol in the virion envelope is essential for dengue virus infectivity.•The four dengue serotypes are similarly inactivated by cholesterol-extracting drugs.•Dengue virus uncoating is blocked in infection with cholesterol-depleted virions.•Virion treatment with exogenous cholesterol exert also...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Carro, A.C., Damonte, E.B.
Formato: JOUR
Materias:
Acceso en línea:http://hdl.handle.net/20.500.12110/paper_01681702_v174_n1-2_p78_Carro
Aporte de:
id todo:paper_01681702_v174_n1-2_p78_Carro
record_format dspace
spelling todo:paper_01681702_v174_n1-2_p78_Carro2023-10-03T15:06:13Z Requirement of cholesterol in the viral envelope for dengue virus infection Carro, A.C. Damonte, E.B. Cholesterol Dengue virus Infectivity Methyl-beta-cyclodextrin Viral envelope Virucidal activity capsid protein cholesterol methyl beta cyclodextrin nystatin protein virus protein virus RNA animal cell article cell membrane controlled study cytoplasm dengue endosome host cell human human cell nonhuman priority journal RNA synthesis serotype virion virus attachment virus envelope virus expression virus infectivity virus nucleocapsid Cell Line Cholesterol Dengue Virus Humans Membrane Lipids Virus Internalization Bovinae Dengue virus Miridae •Cholesterol in the virion envelope is essential for dengue virus infectivity.•The four dengue serotypes are similarly inactivated by cholesterol-extracting drugs.•Dengue virus uncoating is blocked in infection with cholesterol-depleted virions.•Virion treatment with exogenous cholesterol exert also a virucidal effect.•Cholesterol in the cell membranes is not required for dengue virus entry. The role of cholesterol in the virus envelope or in the cellular membranes for dengue virus (DENV) infection was examined by depletion with methyl-beta-cyclodextrin (MCD) or nystatin. Pretreatment of virions with MCD or nystatin significantly reduced virus infectivity in a dose-dependent manner. By contrast, pre-treatment of diverse human cell lines with MCD or nystatin did not affect DENV infection. The four DENV serotypes were similarly inactivated by cholesterol-extracting drugs and infectivity was partially rescued when virion suspensions were treated with MCD in the presence of bovine serum. The addition of serum or exogenous water-soluble cholesterol after MCD treatment did not produce a reversion of MCD inactivating effect. Furthermore, virion treatment with extra cholesterol exerted also a virucidal effect. Binding and uptake of cholesterol-deficient DENV into the host cell were not impaired, whereas the next step of fusion between virion envelope and endosome membrane leading to virion uncoating and release of nucleocapsids to the cytoplasm appeared to be prevented, as determined by the retention of capsid protein in cells infected with MCD inactivated-DENV virions. Thereafter, the infection was almost completely inhibited, given the failure of viral RNA synthesis and viral protein expression in cells infected with MCD-treated virions. These data suggest that envelope cholesterol is a critical factor in the fusion process for DENV entry. © 2013 Elsevier B.V. Fil:Damonte, E.B. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. JOUR info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/2.5/ar http://hdl.handle.net/20.500.12110/paper_01681702_v174_n1-2_p78_Carro
institution Universidad de Buenos Aires
institution_str I-28
repository_str R-134
collection Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA)
topic Cholesterol
Dengue virus
Infectivity
Methyl-beta-cyclodextrin
Viral envelope
Virucidal activity
capsid protein
cholesterol
methyl beta cyclodextrin
nystatin
protein
virus protein
virus RNA
animal cell
article
cell membrane
controlled study
cytoplasm
dengue
endosome
host cell
human
human cell
nonhuman
priority journal
RNA synthesis
serotype
virion
virus attachment
virus envelope
virus expression
virus infectivity
virus nucleocapsid
Cell Line
Cholesterol
Dengue Virus
Humans
Membrane Lipids
Virus Internalization
Bovinae
Dengue virus
Miridae
spellingShingle Cholesterol
Dengue virus
Infectivity
Methyl-beta-cyclodextrin
Viral envelope
Virucidal activity
capsid protein
cholesterol
methyl beta cyclodextrin
nystatin
protein
virus protein
virus RNA
animal cell
article
cell membrane
controlled study
cytoplasm
dengue
endosome
host cell
human
human cell
nonhuman
priority journal
RNA synthesis
serotype
virion
virus attachment
virus envelope
virus expression
virus infectivity
virus nucleocapsid
Cell Line
Cholesterol
Dengue Virus
Humans
Membrane Lipids
Virus Internalization
Bovinae
Dengue virus
Miridae
Carro, A.C.
Damonte, E.B.
Requirement of cholesterol in the viral envelope for dengue virus infection
topic_facet Cholesterol
Dengue virus
Infectivity
Methyl-beta-cyclodextrin
Viral envelope
Virucidal activity
capsid protein
cholesterol
methyl beta cyclodextrin
nystatin
protein
virus protein
virus RNA
animal cell
article
cell membrane
controlled study
cytoplasm
dengue
endosome
host cell
human
human cell
nonhuman
priority journal
RNA synthesis
serotype
virion
virus attachment
virus envelope
virus expression
virus infectivity
virus nucleocapsid
Cell Line
Cholesterol
Dengue Virus
Humans
Membrane Lipids
Virus Internalization
Bovinae
Dengue virus
Miridae
description •Cholesterol in the virion envelope is essential for dengue virus infectivity.•The four dengue serotypes are similarly inactivated by cholesterol-extracting drugs.•Dengue virus uncoating is blocked in infection with cholesterol-depleted virions.•Virion treatment with exogenous cholesterol exert also a virucidal effect.•Cholesterol in the cell membranes is not required for dengue virus entry. The role of cholesterol in the virus envelope or in the cellular membranes for dengue virus (DENV) infection was examined by depletion with methyl-beta-cyclodextrin (MCD) or nystatin. Pretreatment of virions with MCD or nystatin significantly reduced virus infectivity in a dose-dependent manner. By contrast, pre-treatment of diverse human cell lines with MCD or nystatin did not affect DENV infection. The four DENV serotypes were similarly inactivated by cholesterol-extracting drugs and infectivity was partially rescued when virion suspensions were treated with MCD in the presence of bovine serum. The addition of serum or exogenous water-soluble cholesterol after MCD treatment did not produce a reversion of MCD inactivating effect. Furthermore, virion treatment with extra cholesterol exerted also a virucidal effect. Binding and uptake of cholesterol-deficient DENV into the host cell were not impaired, whereas the next step of fusion between virion envelope and endosome membrane leading to virion uncoating and release of nucleocapsids to the cytoplasm appeared to be prevented, as determined by the retention of capsid protein in cells infected with MCD inactivated-DENV virions. Thereafter, the infection was almost completely inhibited, given the failure of viral RNA synthesis and viral protein expression in cells infected with MCD-treated virions. These data suggest that envelope cholesterol is a critical factor in the fusion process for DENV entry. © 2013 Elsevier B.V.
format JOUR
author Carro, A.C.
Damonte, E.B.
author_facet Carro, A.C.
Damonte, E.B.
author_sort Carro, A.C.
title Requirement of cholesterol in the viral envelope for dengue virus infection
title_short Requirement of cholesterol in the viral envelope for dengue virus infection
title_full Requirement of cholesterol in the viral envelope for dengue virus infection
title_fullStr Requirement of cholesterol in the viral envelope for dengue virus infection
title_full_unstemmed Requirement of cholesterol in the viral envelope for dengue virus infection
title_sort requirement of cholesterol in the viral envelope for dengue virus infection
url http://hdl.handle.net/20.500.12110/paper_01681702_v174_n1-2_p78_Carro
work_keys_str_mv AT carroac requirementofcholesterolintheviralenvelopefordenguevirusinfection
AT damonteeb requirementofcholesterolintheviralenvelopefordenguevirusinfection
_version_ 1807321157732401152